Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Feature|Articles|June 9, 2025
- Vol 53 No 06
- Volume 53
- Issue 06
En bloc resection of bladder tumor: Is it the way forward?
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Advertisement
Advertisement
More than 2 centuries ago, Philipp Bozzini invented the Lichtleiter, allowing urologists to visualize what is inside the bladder.1 About 1 century ago, Maximilian Stern invented the first resectoscope, which allows us to remove a bladder tumor with electrocautery.2 These 2 crucial elements empowered urologists to perform transurethral resection of bladder tumor (TURBT), a highly revolutionary approach given the limited resources that urologists had at that time.
Related to this article
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement